



## Premature termination of a Clinical Trial

**Full title of the clinical Trial:**

*Phase II Study of Neratinib and Trastuzumab +/- Vinorelbine p.o. in Pre-treated Metastatic HER2-positive Breast Cancer (Ner-Her-1)*

**EudraCT Number:**

*2022-002582-15*

**Sponsor:** Medical University of Graz

**Represented by (name):**

Univ.-Prof. PD Dr. Marija Balic

**Reason for premature termination of the clinical trial:**

*The PI left the centre before the start of the study. No patients were enrolled.*

**Study results (if available):**

*Not applicable.*

**Date and Signature of Sponsor representative:**

**13.01.2025**